OncoSec Medical Incorporated   Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (2008)

Organization Overview

First Clinical Trial
2011
NCT01440816
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

OncoSec Medical Incorporated

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Carcinoma (Phase 2)

Carcinoma, Merkel Cell (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Lymphoma (Phase 2)

Lymphoma, T-Cell, Cutaneous (Phase 2)

Melanoma (Phase 2)

Mycoses (Phase 2)

Mycosis Fungoides (Phase 2)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Triple Negative Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 8